New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are
still increasing worldwide, and approximately 0.2% of the European population suffer from …

The incidence of inflammatory bowel diseases (IBD) in East has risen over the past decade
to become a global disease. The increasing number of studies on the incidence and course …

Background & Aims We compared the efficacy and safety of different first-line (biologic-
naïve) and second-line (prior exposure to tumor necrosis factor [TNF] antagonists) agents for …

OBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)
program was initiated by the International Organization for the Study of Inflammatory Bowel …

Background & Aims A comprehensive knowledge of the natural history of ulcerative colitis
(UC) helps understand disease evolution, identify poor prognostic markers and impact of …

Background and aims. The inflammatory bowel diseases (IBD), Crohn's disease (CD) and
ulcerative colitis (UC), are chronic relapsing disorders of unknown aetiology. The aim of this …

Background & Aims Little is known about in utero exposure to and postnatal clearance of
anti–tumor necrosis factor (anti-TNF) agents in neonates. We investigated the …

Objective The Epi-IBD cohort is a prospective population-based inception cohort of
unselected patients with inflammatory bowel disease from 29 European centres covering a …

Background There are limited data to inform positioning of agents for treating moderate‐
severe ulcerative colitis (UC). Aim To assess comparative efficacy and safety of different …

Background and Aims Inflammatory bowel diseases (IBD), encompassing Crohn's disease
(CD) and ulcerative colitis (UC), are chronic and disabling disorders. Prospective disease …